EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Design, Synthesis and Biological Evaluation of Quinazolinamine Derivatives as Breast Cancer Resistance Protein and P-Glycoprotein Inhibitors with Improved Metabolic Stability

Chao-Yun Cai, Qiu-Xu Teng, Megumi Murakami iD, Suresh V Ambudkar iD, Zhe-Sheng Chen iD, Vijaya L Korlipara

Biomolecules · 2023

DOI: 10.3390/biom13020253 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomolecules, 2023. Verfasst von Chao-Yun Cai und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, 8000 Utopia Parkway, Queens, New York, NY 1143…. Hauptthemen laut MEDLINE: Azides, Breast Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A series of twenty-two quinazolinamine derivatives showing potent inhibitory activities on breast cancer resistance protein (BCRP) and p-glycoprotein (P-gp) were synthesized. A cyclopropyl-containing quinazolinamine 22 was identified as a dual BCRP and P-gp inhibitor, while azide-containing quinazolinamine 33 showed BCRP inhibitory activity. These lead compounds were further investigated in a battery of mechanistic experiments. Compound 22 changed the localization of BCRP and P-gp in cells, thus inhibiting the efflux of anticancer drugs by the two ATP-binding cassette (ABC) transporters. In addition, both 22 and 33 significantly stimulated the ATP hydrolysis of the BCRP transporter, indicating that they can be competitive substrates of the BCRP transporter, and thereby increase the accumulation of mitoxantrone in BCRP-overexpressing H460/MX20 cells. Azide derivative 33, exhibited a greater inhibitory effect on BCRP after UV activation and can serve as a valuable probe for investigating the interactions of quinazolinamine derivatives with BCRP. Notably, the dual BCRP and P-gp inhibitors 4–5, 22–24, 27, and BCRP inhibitor 33 showed improved metabolic stability compared to Ko143.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AzidesBreast NeoplasmsHumansFemaleATP Binding Cassette Transporter, Subfamily G, Member 2Neoplasm ProteinsATP Binding Cassette Transporter, Subfamily BATP-Binding Cassette TransportersATP Binding Cassette Transporter, Subfamily B, Member 1Adenosine TriphosphateDrug Resistance, Neoplasm

Stichwörter der Autor:innen

ABC transportersBCRPP-gpmultidrug resistancequinazolinamine derivatives

Substanzen

ATP Binding Cassette Transporter, Subfamily G, Member 2AzidesNeoplasm ProteinsATP Binding Cassette Transporter, Subfamily BATP-Binding Cassette TransportersATP Binding Cassette Transporter, Subfamily B, Member 1Adenosine Triphosphate

Autor:innen und Institutionen

  • Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, 8000 Utopia Parkway, Queens, New York, NY 11439, USA.
  • Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 37 Convent Drive, Bethesda, MD 20892, USA.

ORCID-Profile: Megumi Murakami, Suresh V Ambudkar, Zhe-Sheng Chen

Zitieren

APA

Cai, C. Y., Teng, Q. X., Murakami, M., Ambudkar, S. V., Chen, Z. S., & Korlipara, V. L. (2023). Design, Synthesis and Biological Evaluation of Quinazolinamine Derivatives as Breast Cancer Resistance Protein and P-Glycoprotein Inhibitors with Improved Metabolic Stability. Biomolecules. https://doi.org/10.3390/biom13020253

Vancouver

Cai CY, Teng QX, Murakami M, Ambudkar SV, Chen ZS, Korlipara VL. Design, Synthesis and Biological Evaluation of Quinazolinamine Derivatives as Breast Cancer Resistance Protein and P-Glycoprotein Inhibitors with Improved Metabolic Stability. Biomolecules. 2023. doi:10.3390/biom13020253

BibTeX
@article{Cai2023,
  author = {Cai, Chao-Yun and Teng, Qiu-Xu and Murakami, Megumi and Ambudkar, Suresh V and Chen, Zhe-Sheng and Korlipara, Vijaya L},
  title = {Design, Synthesis and Biological Evaluation of Quinazolinamine Derivatives as Breast Cancer Resistance Protein and P-Glycoprotein Inhibitors with Improved Metabolic Stability},
  journal = {Biomolecules},
  year = {2023},
  doi = {10.3390/biom13020253}
}
Kostenlos starten →